Display search results for ** instead (16 products)

Showing 11-16 of 16

USD 500.00

USD 375.00 save 25 %

This Vital Signs issue discusses the Danaher's acquisition of Cepheid for nearly $4 Billion in cash, and Orphan Drug Expenditures in the United States: A Historical and Prospective Analysis, 2007–2013.

USD 600.00

USD 450.00 save 25 %

26 Sep 2016  |  Global

IoT Security: The Impossible Mission

2015 was the year for Internet of Things (IoT) in term of positive perspectives, growth potential, industry impacts, and new revenue sources. Frost & Sullivan revealed that by 2020, the total global market will reach over $200 billion and every household will have at least 10 connected devices. In the coming year, the construction market will emerg...

USD 500.00

USD 375.00 save 25 %

This Vital Signs issue discusses the clinical diagnostics laboratory tests payment system, approval of a Zika test kit, the impact on innovation of mergers in the pharma/biotech industry, and national healthcare expenditure projections through 2025.

USD 600.00

USD 450.00 save 25 %

This issue of Vital Signs, released on February 4, 2014, discusses Roches collaboration with Foundation Medicine, Novartis potential anti-aging drug, and DNA Electronics; acquisition of nanoMR, Inc.

USD 500.00

USD 375.00 save 25 %

This issue of Vital Signs, released on August 5, 2014, discusses the Senators plead to the FDA for the quick action regarding draft guidance on laboratory developed tests (LDTs), Synthetic Biologys Series A funding round, Roches investment in Stratos Genomics, and Indias cap on drug prices.

USD 500.00

USD 375.00 save 25 %

Showing 11-16 of 16